Loxagen, spun out of technology matured at Havard University, is developing first in class therapeutics for diseases with strong unmet needs. Our team is comprised of experienced industry personnel who have taken multiple drugs to the clinic and world-renowned clinicians. With the help of $8 M non-dilutive funding, we have completed most of the IND enabling studies for our lead molecule and raising funds to complete IND submissions and Phase 1 clinical studies for multiple indications within the next 2 years